RxDoctor Payments Data

Allison Geier, MD

Family Medicine · Watertown, SDNPI 1629290440

Payments from drug & device makers

$342in general payments, 2019–2025

Across 19 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$183
  • Pfizer$71
  • Nevro Corp.$26
  • Astellas Pharma US Inc$17
  • Abbott$17
  • GSK$14
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$342100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)10$183
Pfizer4$71
Nevro Corp.1$26
Astellas Pharma US Inc1$17
Abbott1$17
GSK1$14
Amgen1$14

How this compares

$342 in reported general payments places this provider in the 60th percentile of 408 family medicine providers in South Dakota.

See all family medicine providers in South Dakota

Medicare billing

Part B allowed, 2024
$329,930
Medicare patients
261
Services billed
15,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$94,081
TrulicityDulaglutide42$46,735
XareltoRivaroxaban41$28,991
MyrbetriqMirabegron36$18,936
MounjaroTirzepatide18$18,081
Breo ElliptaFluticasone/Vilanterol20$14,966
Repatha SyringeEvolocumab21$11,031
OzempicSemaglutide12$10,801
Tresiba Flextouch U-100Insulin Degludec11$10,232
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$9,665
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,114
RestasisCyclosporine12$7,795
LinzessLinaclotide12$6,532
Levothyroxine Sodium696$5,192
Incruse ElliptaUmeclidinium Bromide13$4,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$71$94,081107 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta$14$28,91446 claims
Astellas Pharma US IncMyrbetriq$17$18,93636 claims
AbbVieRestasis, Linzess, Synthroid$183$18,07059 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 408 family medicine providers in South Dakota.

Other family medicine in Watertown

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →